Literature DB >> 2259271

Plasma concentrations of endothelin in patients with abnormal vascular reactivity. Effects of ergometric exercise and acute saline loading.

H G Predel1, H Meyer-Lehnert, A Bäcker, H Stelkens, H J Kramer.   

Abstract

We measured circulating concentrations of endothelin, a recently discovered vasoconstrictor peptide produced by vascular endothelial cells, in healthy subjects and in patients with abnormal vascular reactivity. Endothelin concentrations were determined by radio-immunoassay after extraction of plasma using Sep-Pak C-18 cartridges in healthy subjects (n = 20), in patients with diabetes mellitus type I (n = 10), in patients with mild to moderate essential hypertension (n = 12) and in non-dialyzed patients with stable chronic renal failure (n = 12). Plasma concentrations were similar in healthy controls, in diabetics and in hypertensive patients averaging 5.0 +/- 0.6 pg/ml, 4.7 +/- 0.2 pg/ml and 6.5 +/- 1.0 pg/ml, respectively. In contrast, plasma concentrations of endothelin were markedly elevated in patients with chronic renal failure averaging 16.6 +/- 2.9 pg/ml (p less than 0.005). No correlations were observed between serum creatinine concentrations ranging from 124 to 850 mumol/l or blood pressure and plasma concentrations of endothelin. Bicycle ergometric exercise in six healthy subjects and an acute modest i.v. saline load of 1,000 ml of 0.45% NaCl administered within 60 min in six patients with mild essential hypertension did not affect plasma concentrations of endothelin. Thus, it is unlikely that vascular synthesis of endothelin is related to acute physiological changes in systemic hemodynamics or to the circulatory and renal responses to acute extracellular fluid volume (ECFV) expansion. A potential role of endothelin, however, in the control of regional blood flow cannot be excluded. Elevated plasma concentrations of endothelin observed in patients with chronic renal failure require further investigations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2259271     DOI: 10.1016/0024-3205(90)90286-z

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  The vascular endothelin system in hypertension--recent patents and discoveries.

Authors:  Meri M Hynynen; Raouf A Khalil
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2006-01

Review 2.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes.

Authors:  E J Stevens; D R Tomlinson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

4.  Levels of plasma neuropeptide Y and other vasoactive substances during head-up tilt in normal and essential hypertensive subjects.

Authors:  F Veglio; D Schiavone; G Mengozzi; P Molino; L Chiandussi
Journal:  Clin Auton Res       Date:  1995-04       Impact factor: 4.435

5.  Endothelin-1 Serum Concentration in Pediatric Chronic Idiopathic Uveitis.

Authors:  Katarzyna Powierza; Jolanta Sawicka-Powierza; Beata Urban; Beata Żelazowska-Rutkowska; Bogdan Cylwik; Bożena Mikołuć; Olga Kowalewska; Alina Bakunowicz-Łazarczyk
Journal:  Clin Ophthalmol       Date:  2021-01-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.